The widespread use of the atypical antipsychotic, clozapine, has been limited due to considerable risks of rare but potentially fatal adverse side effects. Among these adverse effects, cardiac side effects such as myocarditis are under-appreciated despite their association with increased risk of death. Unfortunately, our ability to identify those at greatest risk for clozapine-associated cardiac side effects is poor.
In response to this gap in knowledge, we have established the Pharmacogenetics of Clozapine-Induced Myocarditis (PROCLAIM) Consortium. The PROCLAIM Consortium is uniting investigators around the world to uncover genomic markers that could be used preemptively by clinicians to identify those patients at highest risk for myocarditis from clozapine therapy and identify the mechanism by which clozapine induces myocardial inflammation and damage.
We invite all clinicians and/or investigators who have cared for and/or studied individuals that have developed myocarditis following clozapine exposure to join the PROCLAIM Consortium. We are particularly interested in members who can contribute samples and/or genomic data that would enable pooled analyses to be performed. Please contact us if you are interested in becoming a site.
The PROCLAIM Consortium was initiated in 2017 by Dr Chad Bousman and Prof Christos Pantelis at the University of Melbourne. The first nine participants were recruited from the Adult Mental Health Rehabilitation Unit at Sunshine Hospital in Melbourne, Australia. In late 2017, Dr Bousman and the PROCLAIM Consortium relocated to the University of Calgary, maintaining the University of Melbourne as a study site. Currently there are 14 sites covering Australia, Canada, Turkey and the US (see below for site details and investigators affiliated with the study).
University of Melbourne Establishment Grant (2017)
University of Calgary, Cumming School of Medicine (2017-2020)
University of Calgary, VPR Catalyst Grant (2021)
Created by: Diogo Marques, Nazanin Vazari, & Ankita Narang
1. Identify clinical factors associated with clozapine-induced myocarditis.
2. Discover genomic markers that could be developed into a clinical tool to identify patients at high risk for myocarditis caused by clozapine.
3. Understand how clozapine induces myocardial inflammation and damage and ultimately identify a modifiable mechanism.
Chad Bousman, MPH, PhD
University of Calgary
University of Calgary
Steven Greenway, MSC, MD, FRCPC
Rory Sellmer, BPE, MD, FRCPC
David Crockford, MD, FRCPC, DABPN, FAPA, FCPA
University of Toronto, Centre for Addictions & Mental Health
Gary Remington, MD, PhD
University of Ottawa
Jess Fiedorowicz, M.D., Ph.D.
William Osler Health System
Shailesh Nadkarni, MBBS, MHSA
Amlan Das, MD
Charles Ohene-Darkoh, MD
University of British Columbia
Robert Stowe, MD, ABPN, FRCPC
University of Saskatchewan
Rohit Lodhi, PhD, FRANZCP, MRCPsych, MD Psych, D.P.M
University of Melbourne
Christos Pantelis, MBBS, MRCPsych, MD, FRANZCP
Naveen Thomas, MBBS
Mahesh Jayaram, MBBS, DPM, MMedSc
Kathlyn Ronaldson, BSc, MSc, DPhil, MPH
John McNeil, MBBS, MSc, PhD, FRACP, FAFPHM
Paul Lacaze, PhD
University of New South Wales, Neuroscience Research Australia
Cynthia Shannon Weickert, BA, Mphil, PhD
University of Queensland
Dan Siskind, MD, PhD
Karl Winckel, BPharm
The University of Newcastle
Murray Cairns, PhD
James Cook University
Tahnee L Bridson, MBBS BMedSc
Kevin J Li, MD
Lynn DeLisi, MD
Ronald Gurerra, MD
Jerry Fleming, MPH
Hacettepe University (Turkey)
A. Elif Anil Yagcioglu, MD